ERBB2 and breast cancer: Notably, in the context of human epidermal growth factor receptor 2 (HER2)–positive breast cancer patients' response to anti-HER2 therapy, Ji et al. (33) also discovered that DNAJC3 can regulate the HER2 response kinase pathway through the PI3K and MAPK signaling pathways.